Investigational drug · Phase 2
STM-416
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-muscle-invasive Bladder Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "STM-416"
First trial start
2023
Jul 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STM-416", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-muscle-invasive Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "STM-416" as an intervention, largest first.
SURGE TherapeuticsIndustry
NCT05710848 · 75 participants (planned) · Start Jul 11, 2023 · Primary completion May 2026
Drug: STM-416 · For: Non-muscle-invasive Bladder Cancer
Sites: Mesa, Arizona; Tucson, Arizona; Little Rock, Arkansas · 20 sites in all
SURGE TherapeuticsIndustry
NCT06450106 · 18 participants (planned) · Start May 8, 2025 · Primary completion Sep 2026
Drug: STM-416p · For: Prostate Cancer
Sites: Tucson, Arizona; Gainesville, Florida; Melbourne N., Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.